Welcome to our dedicated page for Clorox Co Del SEC filings (Ticker: CLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clorox Company filings document formal disclosures for an operating consumer-products issuer with a portfolio of household, food, grilling, pet-care, water-filtration and personal-care brands. Its Form 8-K reports include quarterly operating and financial results, supplemental financial information, outlook-related materials and Regulation FD disclosures tied to the company's reported performance.
Clorox filings also record governance and capital-market matters, including shareholder meeting results, director elections, advisory executive-compensation votes, auditor ratification, executive transition disclosures, material-event reports, material agreements, capital-structure disclosures and risk-factor updates when applicable. These records connect the company's brand portfolio, completed acquisitions and public-company governance to its SEC reporting obligations.
Clorox director Christopher J. Williams reported routine compensation-related awards of Deferred Stock Units. He acquired 265.3672 units on March 31, 2026 and 212.6390 units on February 13, 2026, with each unit representing one share of Clorox common stock.
Some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan and some in lieu of quarterly director fees. These Deferred Stock Units will be settled entirely in Clorox stock when Williams retires or otherwise leaves the board, bringing his reported Deferred Stock Unit balance to 22,074.5818 units held directly.
Clorox (CLX) director Russell J. Weiner reported routine compensation-related acquisitions of Deferred Stock Units. On February 13, 2026, he received 172.3630 Deferred Stock Units, and on March 31, 2026, he received 325.6779 Deferred Stock Units, each on a 1-for-1 basis linked to Clorox common stock.
According to the footnotes, some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan and others in lieu of quarterly director fees. The units will be settled entirely in Clorox stock upon his retirement or other termination of service as a director. Following these awards, his reported balance is 18,004.0034 Deferred Stock Units held directly.
Clorox director Matthew J. Shattock reported routine equity-based compensation in the form of deferred stock units. He acquired 506.6101 deferred stock units on March 31, 2026 and 191.2909 units on February 13, 2026, each on a 1-for-1 basis with Clorox common stock.
The units were received through dividend reinvestment and in lieu of quarterly director fees under the Independent Directors' Deferred Compensation Plan and will be settled in Clorox stock after his retirement or other termination of board service. Following these awards, he directly holds 20,126.2673 deferred stock units.
Clorox director Pierre R. Breber reported routine compensation-related awards of Deferred Stock Units tied 1-for-1 to Clorox common stock. On March 31, 2026, he acquired 325.6779 Deferred Stock Units, bringing his holdings to 3100.0674 units. On February 13, 2026, he had received an additional 27.0502 units.
According to the disclosures, some Deferred Stock Units were acquired through dividend reinvestment during the fiscal year under the Independent Directors' Deferred Compensation Plan and some were received in lieu of quarterly director fees. These units will be settled entirely in Clorox stock when Breber retires or otherwise leaves the board, and do not reflect open-market buying or selling.
Clorox director Stephanie Plaines reported awards of deferred stock units that increase her equity-based compensation stake. She acquired 265.3672 deferred stock units on March 31, 2026 and 72.7316 units on February 13, 2026, both at a stated price of $0.00 per unit as non-cash awards.
The units are credited 1-for-1 in relation to Clorox common stock and arise from dividend reinvestment during the fiscal year and receipt of deferred units instead of quarterly director fees under the Independent Directors' Deferred Compensation Plan. Following the latest award, she holds a total of 7,725.0486 deferred stock units, which will be settled entirely in Clorox stock upon her retirement or other termination of board service.
The Clorox Company completed its acquisition of GOJO Industries, makers of Purell, on April 1, 2026. Clorox purchased all issued and outstanding membership interests of GOJO under a membership interest purchase agreement with GOJO Industries Holdings and its shareholders. The acquired business will operate as Clorox Purell, led by President Carey Jaros, based in Akron, Ohio, with existing facilities remaining in Ashland, Cuyahoga Falls and Wooster, Ohio. Clorox describes the combination as expanding its health and hygiene portfolio and reinforcing its strategy to deliver comprehensive solutions for both consumers and institutional customers.
The Vanguard Group filed an Amendment No. 13 to a Schedule 13G/A reporting that it beneficially owns 0 shares of Clorox Co. Common Stock and holds 0% of the class. The filing explains an internal realignment effective January 12, 2026, with certain subsidiaries reporting ownership separately in reliance on SEC Release No. 34-39538.
Clorox executive Chris T. Hyder reported a small tax-related share disposition. On the vesting of restricted stock, 41 shares of Clorox common stock were withheld by the company at $108.73 per share to satisfy tax obligations, a routine non-market transaction.
After this withholding, Hyder directly holds 34,969 shares of Clorox common stock, which the disclosure notes includes 10 shares acquired through a dividend reinvestment feature of the company’s stock incentive plan.
Clorox executive Stacey Grier reported a small, routine share disposition tied to taxes rather than a market trade. On vesting of restricted stock, the company withheld 32 shares of common stock at a value of $108.73 per share to cover tax obligations.
After this tax-withholding disposition, Grier directly holds 32,116 Clorox shares. This total includes 10 shares acquired through a dividend reinvestment feature of the company’s stock incentive plan, indicating the filing reflects compensation and administrative activity rather than an open-market sale.
The Clorox Company entered into two new unsecured credit facilities totaling $2.25 billion to support its planned acquisition of GOJO Industries, maker of PURELL, and for general corporate purposes.
The first is a $1.0 billion 364-day revolving credit agreement available in U.S. dollars for general corporate use. Borrowings are available until March 5, 2027, and Clorox may convert outstanding amounts into a term loan maturing March 5, 2028. Pricing is based on either a base rate or Term SOFR plus a margin tied to Clorox’s senior unsecured credit rating, and a quarterly facility fee also varies with that rating.
The second is a $1.25 billion delayed draw term credit agreement available at the closing of the GOJO acquisition to finance part of the purchase price, pay related fees and expenses, and repay certain GOJO debt, with any remaining amounts available for general corporate purposes. Loans under this facility mature on March 5, 2027, and undrawn commitments terminate on the earliest of December 31, 2026, termination of the acquisition agreement, or closing of the acquisition without using this financing. Both agreements include customary covenants and events of default, with a consolidated interest coverage ratio as the sole financial covenant and mandatory reductions or prepayments from certain future debt or equity proceeds.